VLA
Click for more information
0.00% $1.75 viralytics limited

Mercks revenue from Keytruda in the Oct 17 quarter was...

  1. 3rddoor
    91 Posts.
    lightbulb Created with Sketch. 15
    clock Created with Sketch.
    23/02/18
    13:46
    Post #: 31290901
    Mercks revenue from Keytruda in the Oct 17 quarter was US$1billion, so extrapolating the yearly revenue will be US$4billion so if Cavatak makes Keytruda 10% more sales Merck will have made their money in a year (give or take the cost of finalizing the approvals). Given that Cavatak actually showed better efficacy and safety profiles in 2015 than their product this valuation seems cheap.
    Last edited by 3rddoor: 23/02/18
    VLA Price at posting: $1.69 Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 5  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Results wrap: Wesfarmers, Southern Cross Media, Qantas
right-arrow Created with Sketch.
NEWS Government spend has to stop or interest rates must rise, property expert
right-arrow Created with Sketch.
NEWS Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch
right-arrow Created with Sketch.
EMR Emerald expands underground resource by 105Koz at Cambodian gold mine Okvau
right-arrow Created with Sketch.
HYT Twiggy Forrest to acquire 40% of native hydrogen explorer – not long after putting Fortescue Future Industries to sleep
right-arrow Created with Sketch.
NEWS Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip
right-arrow Created with Sketch.
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.